Business
Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery™, Biomarker Research, and Novel Antibodies at Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026
NEWTON, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced new research findings at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD), taking place March 17-21, in Copenhagen and online. Shared in one oral and two po
About this update from Acumen Pharmaceuticals, Inc.
[{"type":"image","alt":"Acumen Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Acumen Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":62,"url":"https://media.zenfs.com/en/globenewswire.com/cbb5dd6e9a075046255d7d2e82373879"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5J.4IvnfhFM_bTHIo4TE3Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/cbb5dd6e9a075046255d7d2e82373879","width":300,"height":62}},"lazy":false},{"type":"text","content":"NEWTON, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced new research findings at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD), taking place March 17-21, in Copenhagen and online. Shared in one oral and two poster presentations, the data showcase efforts to advance AD treatment through three key areas which include: developing enhanced brain delivery (EBD™) methods for sabirnetug by developing bispecific antibodies that additionally target Transferrin receptors to improve drug penetration across the blood-brain barrier; evaluating novel biomarker approaches using NULISAseq™ technology to better monitor treatment responses in the central nervous system; and creating highly selective antibodies that specifically target toxic AβOs while avoiding non-toxic monomeric forms of the protein.","length":1085,"tagName":"p"},{"type":"text","content":"“These presentations collectively demonstrate how we’re addressing the key challenges that have limited success in Alzheimer’s drug development – delivery, measurement, timing, and selectivity,” said Jim Doherty, President and Chief Development Officer of Acumen. “Our enhanced brain delivery work with JCR Pharmaceuticals tackles the fundamental problem of increasing bioavailability of therapeutics across the blood-brain barrier, while our biomarker research provides better tools for measuring treatment effects – expanding our understanding of these effects and early disease mechanisms. Lastly, our novel antibody development is purposely driving toward an increased selectivi...